J J Vredenburgh

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support
    J J Vredenburgh
    Duke University Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 3:91-7. 1997
  2. ncbi request reprint Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemothera
    James J Vredenburgh
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 12:195-203. 2006
  3. ncbi request reprint Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:1253-9. 2007
  4. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
  5. pmc Experience with irinotecan for the treatment of malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 11:80-91. 2009
  6. doi request reprint Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
    James J Vredenburgh
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 82:58-66. 2012
  7. pmc Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 15:1329-34. 2010
  8. pmc The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma
    James J Vredenburgh
    Departments of Surgery, Neurology, Pediatrics, Medicine, Radiation Oncology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina
    Clin Cancer Res 17:4119-24. 2011
  9. ncbi request reprint A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone
    J J Vredenburgh
    Division of Medical Oncology Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 37:1009-15. 2006
  10. ncbi request reprint Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support
    D A Rizzieri
    Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA
    J Clin Oncol 17:3064-74. 1999

Detail Information

Publications92

  1. ncbi request reprint The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support
    J J Vredenburgh
    Duke University Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 3:91-7. 1997
    ..A comparison with other prognostic factors and characteristics of the tumor may determine the significance of the tumor contamination of the bone marrow...
  2. ncbi request reprint Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemothera
    James J Vredenburgh
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 12:195-203. 2006
    ..Salvage HDC converted 30% of partial responders to complete responders with similar survivals. The addition of novel targeted therapies to intensive-dose chemotherapy regimens may further improve survival in metastatic breast cancer...
  3. ncbi request reprint Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 13:1253-9. 2007
    ..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma...
  4. ncbi request reprint Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:4722-9. 2007
    ..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan...
  5. pmc Experience with irinotecan for the treatment of malignant glioma
    James J Vredenburgh
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 11:80-91. 2009
    ..Toxicities associated with irinotecan have been manageable; the most important dose-limiting toxicities are neutropenia and diarrhea. Irinotecan-based chemotherapy of malignant glioma merits further study...
  6. doi request reprint Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
    James J Vredenburgh
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 82:58-66. 2012
    ..To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)...
  7. pmc Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
    James J Vredenburgh
    Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 15:1329-34. 2010
    ..We assessed corticosteroid use in patients with recurrent glioblastoma treated with bevacizumab (BEV) in the BRAIN study (J Clin Oncol 2009;27:4733-4740)...
  8. pmc The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma
    James J Vredenburgh
    Departments of Surgery, Neurology, Pediatrics, Medicine, Radiation Oncology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina
    Clin Cancer Res 17:4119-24. 2011
    ..To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective...
  9. ncbi request reprint A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone
    J J Vredenburgh
    Division of Medical Oncology Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 37:1009-15. 2006
    ....
  10. ncbi request reprint Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support
    D A Rizzieri
    Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA
    J Clin Oncol 17:3064-74. 1999
    ..We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy...
  11. ncbi request reprint Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients
    A Desjardins
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:2026. 2008
    ..We report a phase II trial to determine the correlation between vascular permeability and radiographic response in GBM patients treated with irinotecan and bevacizumab...
  12. ncbi request reprint Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM)
    J J Vredenburgh
    Duke University Medical Center, Durham, NC
    J Clin Oncol 27:2015. 2009
    ..This study aims to improve the survival of newly diagnosed GBM patients by incorporating an anti-angiogenic agent with RT and TMZ, and adding a topoisomerase I inhibitor, and an anti-angiogenic agent to TMZ post-RT therapy...
  13. ncbi request reprint Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue
    D L Carter
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 17:887-93. 1999
    ..To examine the impact of consolidation radiotherapy (RT) after high-dose chemotherapy with autologous bone marrow rescue (HDC) in patients with advanced breast cancer...
  14. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  15. ncbi request reprint Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial
    A L Sumrall
    Duke University Medical Center, Durham, NC
    J Clin Oncol 29:9090. 2011
    ..Previous reports have shown an incidence of approximately 25% of venous thromboembolic disease in cancer patients receiving concurrent chemotherapy and bevacizumab...
  16. ncbi request reprint Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma
    E Lou
    Duke University Medical Center, Durham, NC
    J Clin Oncol 29:2055. 2011
    ..Given the angiogenic phenotype of GB, we conducted two phase II trials of upfront 5-day temozolomide (TMZ) and Bevacizumab (BV) with or without Irinotecan in patients with newly diagnosed unresectable or multifocal GB...
  17. ncbi request reprint Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma
    J N Rich
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:2022. 2008
    ..In this study, we evaluate the efficacy of bevacizumab when combined with etoposide, a topoisomerase inhibitor, in patients with recurrent malignant glioma (MG)...
  18. ncbi request reprint Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
    S Sathornsumetee
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:13008. 2008
    ..Bevacizumab is dosed at 10 mg/kg intravenously every two weeks. Erlotinib is orally administered daily with 200 mg/day for patients not on EIAC and 650 mg/day for patients on EIAC...
  19. ncbi request reprint Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG)
    J P Kirkpatrick
    Duke University Medical Center, Durham, NC University of Pittsburgh Cancer Institute, Pittsburgh, PA
    J Clin Oncol 26:2057. 2008
    ..Imatinib mesylate (IM) and hydroxyurea (H) have recently demonstrated promising anti-glioma activity. We attempt to extend the efficacy of IM and H by adding a VEGF receptor inhibitor, vatalanib (V; PTK787)...
  20. ncbi request reprint Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas
    S A Wagner
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:2021. 2008
    ..2021 Background: Recurrent grade III-IV malignant gliomas have a dismal prognosis and effective salvage therapies are limited...
  21. pmc Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
    D A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA
    Br J Cancer 107:1481-7. 2012
    ..We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries...
  22. ncbi request reprint Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Hematother Stem Cell Res 11:659-68. 2002
    ....
  23. pmc Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sith Sathornsumetee
    Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
    J Clin Oncol 26:271-8. 2008
    ....
  24. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  25. ncbi request reprint Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea
    M E Salacz
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:2071. 2008
    ....
  26. ncbi request reprint Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM)
    K Peters
    Duke University Medical Center, Durham, NC
    J Clin Oncol 27:e13025. 2009
    ..Given the angiogenic phenotype of GBM, we conducted a phase II trial of upfront BV and 5-day TMZ in newly diagnosed unresectable or multifocal GBMs...
  27. ncbi request reprint Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM)
    H S Friedman
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:2062. 2008
    ..The antiglioma activity of EGFR inhibitors is enhanced by inhibitors of the mammalian target of rapamycin (mTOR), such as sirolimus, in preclinical studies...
  28. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme
    J A Quinn
    Duke University Medical Center, Durham, NC Keryx Biopharmaceuticals, Inc, Memphis, TN
    J Clin Oncol 26:2084. 2008
    ..This trial was designed to define the maximum tolerated dose (MTD) of temozolomide administered for 5 consecutive days in combination with O6-benzylguanine (O6-BG)...
  29. ncbi request reprint A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma
    H S Friedman
    Duke University Medical Center, Durham, NC
    J Clin Oncol 27:e13024. 2009
    ..The current study was designed to determine the MTD and DLT of sunitinib (S), a once-daily, oral selective inhibitor of VEGFR when combined with irinotecan (I), a topoisomerase-1 inhibitor among recurrent MG patients...
  30. ncbi request reprint Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas
    S Sathornsumetee
    Duke University Medical Center, Durham, NC
    J Clin Oncol 27:2045. 2009
    ..B plus E was associated with clinical benefit in several solid tumors. We performed a single-arm, phase II study to evaluate the efficacy of B and E in patients with recurrent MG...
  31. pmc Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
    D A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Br J Cancer 101:1986-94. 2009
    ..We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial...
  32. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  33. ncbi request reprint Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma
    K C Cuneo
    Duke University Medical Center, Durham, NC
    J Clin Oncol 29:2082. 2011
    ..Retrospective studies of stereotactic radiosurgery (SRS) for recurrent glioma have also suggested improved outcomes, particularly when BVZ is administered after SRS...
  34. ncbi request reprint Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM)
    J J Vredenburgh
    Duke University Medical Center, Durham, NC
    J Clin Oncol 29:2098. 2011
    ..Hypoxia inducing factor-1 α (HIF-1 α) is an important regulator of VEGF, and topotecan may inhibit HIF-1 α. We performed a phase II trial in newly diagnosed GBM patients, adding bevacizumab and topotecan to standard therapy...
  35. ncbi request reprint A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED)
    A Desjardins
    Duke University Medical Center, Durham, NC Ambit Bioscience, San Diego, CA Ambit Biosciences, San Diego, CA
    J Clin Oncol 29:2070. 2011
    ..EGFR is an important therapeutic target in MG. We performed a pilot study to evaluate the tumor and plasma PK of AC480 among patients with recurrent MG...
  36. ncbi request reprint Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
    R Maron
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:2074. 2008
    ..Bevacizumab is a humanized antibody to VEGF and was active against recurrent GBM when combined with irinotecan. Daily temozolomide may overcome resistance to 5-day temozolomide by depleting MGMT...
  37. ncbi request reprint Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma
    J P Kirkpatrick
    Duke University Medical Center, Durham, NC Duke University Medical Center, Durham, NC
    J Clin Oncol 27:e13007. 2009
    ....
  38. pmc A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme
    M J Paldino
    Department of Radiology, Duke University Medical Center, Durham, NC, USA
    Br J Radiol 85:382-9. 2012
    ....
  39. ncbi request reprint Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantation
    D S McGaughey
    Adult Bone Marrow and Stem Cell Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 7:274-8. 2001
    ..These results are worthy of further study in a randomized clinical trial...
  40. ncbi request reprint Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer
    William P Petros
    Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:698-705. 2002
    ..Prospective strategies, which attempt to individualize AUC, should be evaluated in this setting...
  41. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  42. pmc Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
    Michael A Badruddoja
    Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 9:70-4. 2007
    ..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme...
  43. ncbi request reprint Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue
    Pehr A Lind
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 94:2821-9. 2002
    ..These patients are at risk of developing therapy-related pneumonitis (TRP) during or after radiotherapy (RT)...
  44. doi request reprint Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy
    Mary Lou Affronti
    Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
    Cancer 115:3501-11. 2009
    ..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated...
  45. ncbi request reprint Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials
    D A Reardon
    Duke University Medical Center, Durham, NC
    J Clin Oncol 29:2030. 2011
    ..2030 Background: Although BV benefits most recurrent GBM patients, the duration of benefit is limited and subsequent survival after BV progression is poor due to lack of effective therapeutic options...
  46. ncbi request reprint Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen
    D A Rizzieri
    Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, NC 27710, USA
    Blood 98:3486-8. 2001
    ..The patients are in remission and remain 100% donor as assessed by short tandem repeat analysis of the marrow 6 and 12 months following transplantation...
  47. ncbi request reprint Neurofibromatosis type 2
    S Sathornsumetee
    Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neurology 68:E14. 2007
  48. ncbi request reprint 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 9:183-8. 2003
    ..Approaches to minimize stomatitis and protect normal stem cells from the toxicity of 4HC may improve the tolerance and efficacy of this approach...
  49. ncbi request reprint Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia
    David A Rizzieri
    Duke University Medical Center, Division of Medical Oncology and Transplantation and the Duke Oncology Consortium, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:663-8. 2003
    ....
  50. pmc Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:57-66. 2011
    ..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population...
  51. doi request reprint Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy
    Katherine B Peters
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:155-9. 2011
    ....
  52. ncbi request reprint Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    Steven L McCune
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 43:1007-11. 2002
    ..Alemtuzumab is a monoclonal antibody that offers effective treatment for chemotherapy refractory CLL and PLL and is generally well tolerated in the outpatient setting...
  53. ncbi request reprint Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma
    David A Rizzieri
    Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Network, Duke University, Durham, North Carolina 27710, USA
    Cancer 100:2408-14. 2004
    ..The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL...
  54. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  55. ncbi request reprint Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF
    Cristina Gasparetto
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Cytokine 18:8-19. 2002
    ..In summary, administration of FL in combination with GM-CSF and G-CSF to patients with breast cancer can mobilize large numbers of immature DCs into PBSC leukapheresis collections...
  56. ncbi request reprint Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells
    Nelson J Chao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 8:249-56. 2002
    ..Moreover, the presence of TREC-positive cells within 1 year suggests that thymic recovery is likewise accelerated in non myeloablative compared to myeloablative regimens...
  57. doi request reprint Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing
    Lee W Jones
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 94:79-85. 2009
    ..We conducted a pilot study to explore the feasibility and clinical utility of functional capacity testing to assess physical functioning in recurrent primary malignant glioma patients...
  58. ncbi request reprint Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation
    Magnus Gottfredsson
    Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 98:24-30. 2003
    ..No systemic antifungal prophylaxis was administered. The purpose of the current study was to evaluate the risk and long-term outcome of candidemia in this patient population...
  59. pmc Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  60. ncbi request reprint Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation
    Matthew J Snyder
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Surg Pathol 28:794-800. 2004
    ..All three PTLDs arose 6 to 7 months after NMST and were rapidly fatal. The pathology of the PTLD in all cases was donor origin, EBV positive, diffuse large B-cell lymphoma...
  61. pmc Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 10:330-40. 2008
    ..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population...
  62. pmc Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy
    David A Reardon
    Duke University Medical Center, Neuro Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA
    Expert Opin Biol Ther 8:541-53. 2008
    ..Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors...
  63. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
    ..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide...
  64. doi request reprint The emerging role of anti-angiogenic therapy for malignant glioma
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Curr Treat Options Oncol 9:1-22. 2008
    ..Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy...
  65. ncbi request reprint Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  66. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  67. pmc Temozolomide in children with progressive low-grade glioma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Neuro Oncol 9:161-8. 2007
    ..TMZ given in this schedule was successful in stabilizing disease in a significant proportion of the patients with OPG/PA, with manageable toxicity...
  68. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  69. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  70. ncbi request reprint Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:690-7. 2007
    ..To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype...
  71. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  72. doi request reprint Cryptococcal meningitis in patients with glioma: a report of two cases
    Jonathan D Choi
    Division of Neurosurgery, Department of Surgery, Duke University School of Medicine, Durham, NC 27705, USA
    J Neurooncol 89:51-3. 2008
    ..This report of two cases highlights the importance of examining the efficacy of prophylactic antibiotic and/or antifungal regimens in this patient population due to their increased risk of opportunistic infections...
  73. pmc Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  74. pmc Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
    David A Reardon
    Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2188-98. 2009
    ....
  75. doi request reprint Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme
    Michael J Paldino
    Duke University Medical Center, Department of Radiology, Durham, North Carolina 27710, USA
    J Magn Reson Imaging 29:1199-205. 2009
    ..To quantify the repeatability of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in patients with glioblastoma multiforme...
  76. pmc Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  77. pmc Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
    Annick Desjardins
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:7068-73. 2008
    ..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma...
  78. pmc Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients
    Stephanie L Perry
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:129-34. 2009
    ..Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients...
  79. pmc Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
    ..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence...
  80. doi request reprint Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma
    Richard G Everson
    Division of Neurosurgery, Department of Surgery, Box 3050 Med Ctr, Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC 27710, USA
    Expert Rev Anticancer Ther 8:717-32. 2008
    ....
  81. ncbi request reprint Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab
    M Paldino
    Duke University Medical Center, Durham, NC
    J Clin Oncol 27:2058. 2009
    ....
  82. ncbi request reprint Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results
    D Reardon
    Duke University Medical Center, Durham, NC
    J Clin Oncol 27:2046. 2009
    ..In this study, we evaluate the efficacy of BV plus etoposide (E), a topoisomerase inhibitor, among recurrent MG patients...
  83. doi request reprint Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration
    Hamidreza Aliabadi
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, 220 Sands Building, Research Drive, Box 3050, Durham, NC 27710, USA
    J Neurooncol 98:427-30. 2010
    ..This patient was treated with bevacizumab prior to surgical treatment; radiographic imaging at 3 months, however, showed no significant response. We discuss possible reasons for treatment failure...
  84. ncbi request reprint Molecularly targeted therapy for malignant glioma
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 110:13-24. 2007
    ..In this review, the authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma...
  85. ncbi request reprint Fatal re-expansion pulmonary edema associated with increased lung IL-8 levels following high-dose chemotherapy and autologous stem cell transplant
    Stavros Garantziotis
    Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Respiration 69:351-4. 2002
    ..This suggests that patients who have recently undergone HDC/ASCT may be at increased risk for the development of REPE following thoracentesis...
  86. ncbi request reprint Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?
    Rajesh Bhagat
    Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Chest 126:642-4. 2004
    ..We suggest that pulmonary sarcoidosis may develop following either autologous or allogeneic HSCT, and the prevalence may be 10-fold higher than that of the normal population...
  87. ncbi request reprint Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting
    Eyal Meiri
    Bethesda Memorial Hospital, Comprehensive Cancer Care Center, Boynton Beach, FL 33435 7995, USA
    Curr Med Res Opin 23:533-43. 2007
    ..To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study...
  88. ncbi request reprint Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer
    William P Petros
    West Virginia University Health Sciences Center, PO Box 9300, Morgantown, WV 26506, USA
    J Clin Oncol 23:6117-25. 2005
    ..To evaluate associations between patient survival, pharmacokinetics, and drug metabolism-related genetic polymorphisms in patients receiving a combination chemotherapy regimen for breast cancer...
  89. ncbi request reprint Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer
    Yago Nieto
    Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 10:7136-43. 2004
    ....
  90. ncbi request reprint Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA
    William P Peters
    Cancer and Leukemia Group B, 230 W Monroe St, Suite 2050, Chicago, IL 60606, USA
    J Clin Oncol 23:2191-200. 2005
    ..The prognosis for women with primary breast cancer involving multiple axillary nodes remains poor. High-dose chemotherapy with stem-cell support produced promising results in initial clinical trials conducted at single institutions...
  91. ncbi request reprint High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes
    Monic J Stuart
    Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, California, USA
    Biol Blood Marrow Transplant 8:666-73. 2002
    ..Our study presents long-term favorable results regarding the use of consolidative HDC with autologous hematopoietic support in previously untreated patients with high-risk primary breast cancer...
  92. pmc Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice
    Michael A Badruddoja
    Center for Neurosciences, University of Arizona, Tucson, AZ 85721, USA
    Neuro Oncol 9:240-4. 2007
    ..001), with one toxic death. These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic...